View source for Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial

[[Category:Article]]
[[Category:Covid19]]
{| class="infobox" width=200px
|class="publication"|'''Publication'''
|-
|Title || <ul>[https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v3 Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial]</ul>
|-
|Authors || 
* Zhaowei Chen
* Jijia Hu
* Zongwei Zhang
* ...
* Zhan Zhang
|-
|Journal || medRxiv preprint
|-
|Date|| April 10, 2020
|-
|}

A randomized clinical trial of 62 patients who received hydroxychloroquine or standard therapy showed patients who received hydroxychloroquine had a significantly shorter time to body temperature recovery and cough remission. Notably, 4 patients (13%) in the control group progressed to severe illness whereas no patients treated with hydroxychloroquine progressed.

== Major Issues ==

No major issues identified.

== Minor Issues ==

No minor issues identified.

== Impact ==

This study demonstrated some clinical benefit for hydroxychloroquine in treatment of early stage COVID-19 disease where patients received treatment on average 2.2 days after fever onset and 2 days after cough onset.

== Article Revisions ==

None at this time.

== References ==

<references/>